ARSL p.Arg12Ser
c.36G>C · rs122460151 · VCV11522
Computational evidence
| Protein change | ||
| AlphaMissense | 0.1831 | likely benign |
|---|---|---|
| REVEL | 0.596 | indeterminate |
| SaProt | LLR -5.39 | tolerated |
| ⇒ AlphaMissense and SaProt both call this tolerated; REVEL makes no call. | ||
| Splicing | ||
| SpliceAI | Δ0.65 | acceptor gain · deltas |
| Pangolin | Δ0.59 | gain · loss 0.19 · agrees with SpliceAI · independent |
| Constraint at this position | ||
| Conservation | phyloP 3.2 | GERP 1.1, phastCons 0.98 |
| Regional constraint | o/e 0.63 | unconstrained · MANE · 26 kb · p 8.2e-17 · regional, not allelic |
| Overall | ||
| CADD | 17.32 | PHRED · no single calibrated threshold — expert panels disagree |
ClinVar classifies this uncertain; the computational predictors unanimously lean tolerated — a triage signal, not a reclassification
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
| Ancestry group | Frequency | 1 in |
|---|---|---|
| Finnishnot grpmax-eligible | 0.0107% | 9,333 |
| European (non-Finnish)grpmax | 0.0105% | 9,526 |
| Remaining individualsnot grpmax-eligible | 0.0021% | 47,605 |
Finnish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.
Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.
Variant & gene context
- Gene
- ARSL
- Protein
- p.Arg12Ser
- Coding
- c.36G>C
- MANE Select
- NM_000047
- dbSNP
- rs122460151
- Type
- single nucleotide variant
- Location
- chrX:2958423 (GRCh38)
- Structure
- AlphaFold pLDDT 92.57
- Residue 12
- a UniProt-annotated variant site (in cdpx1; no effect on arylsulfatase activity, protein stability and localization to the golgi apparatus)
Similar variants
- ARSL c.1289+1G>A Pathogenic/Likely pathogenic ★★ same condition
- ARSL c.24-2A>G Likely pathogenic ★★ same condition
- ARSL p.Gly117Arg Pathogenic/Likely pathogenic ★★ same condition
- ARSL p.Gly73Ser Likely pathogenic ★★ ⚠ same condition
- ARSL p.Ala182Thr Uncertain significance ★★ ⚠ same condition
- ARSL p.Ala251Val Uncertain significance ★★ ⚠ same condition
- ARSL p.Ala45Val Uncertain significance ★★ ⚠ same condition
- ARSL p.Arg190His Uncertain significance ★★ ⚠ same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/arsl-p-arg12ser (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown